PSD-95基因沉默对神经病理性疼痛大鼠疼痛行为学的干预作用
|
摘要
目的：
已有实验证明PSD-95与神经病理性疼痛密切相关,而RNA干扰(RNA interference, RNAi)技术是近年研究比较热门的治疗方向。本研究旨在利用RNAi技术沉默大鼠脊髓PSD-95基因,并观察此方法治疗神经病理性疼痛的效果。
方法：
将30只雄性SD大鼠随机分成6组(n=5),分别为空白对照,假手术组(3天和7天),以及CCI模型(3天、7天、14天)组,通过测量机械性痛阈和热痛阈来判断CCI模型是否成功。术后第3天、第7天、第14天分别处死大鼠,留取脊髓标本,进行real-time PCR分析PSD-95mRNA表达水平的变化。取不同重量大鼠建立鞘内置管给药模型,置管次日鞘内注射2%利多卡因,判断鞘内置管是否成功,并评价不同重量大鼠置管深度与效果的关系。选取合适重量大鼠,分组后(n=6)进行鞘内置管,鞘内给予PSD-95小干扰RNA(small interfering RNA, siRNA),最后一次给药后1天、3天、5天分别测量痛行为变化,并于1天和5天处死动物,留取脊髓标本,进行real-time PCR分析PSD-95siRNA表达的变化。选取合适重量大鼠,分组(n=5)后进行鞘内置管,置管后3-4天建立坐左侧骨神经CCI(chronic constriction injury,'慢性压迫性损伤)模型,并鞘内分别给予PSD-95siRNA、生理盐水、转染试剂(i-FectTM)、阴性对照siRNA,在给药后1天和5天分别测量痛阈,并处死动物,留取脊髓标本,进行real-time PCR分析PSD-95mRNA表达水平的变化。
结果：
大鼠CCI模型手术侧后足机械性痛阈和热痛敏阈值明显下降(P<0.05),但脊髓背角PSD-95mRNA表达无明显变化。正常大鼠中,鞘内注射PSD-95siRNA可降低大鼠脊髓背角PSD-95mRNA表达水平(P<0.05),但对其痛阈无显著影响。鞘内注射PSD-95siRNA可明显缓解CCI模型大鼠的神经病理性疼痛(P<0.05)。
结论：
CCI模型大鼠其脊髓背角PSD-95mRNA表达水平无显著改变,鞘内注射PSD-95siRNA可以明显缓解CCI模型大鼠的热痛觉过敏和机械性痛觉异常。
Objective:
It is taught that PSD-95is involved in the generation and development of chronic neuropathic pain. RNAi (RNA interference) technique and small interfering RNA (siRNA) now offer a powerful and highly specific tool for therapeutic gene silencing. The aim of this study is to investigate the efficiency of PSD-95gene silencing by siRNA, together with its therapeutic effect on chronic constriction injury model rats.
Methods:
Ninety-six male SD rats, weighting200-250g were randomly divided into6groups (n=5for each group):Naive, Sham(sham3d and sham7d), CCI(CCI3d, CCI7d and CCI14d). Mechanical allodynia and thermal hyperalgesia were measured to evaluate the success of the model. The rats were executed on3rdd、7thd、14thd after the surgery, and the level of PSD-95mRNA was compared among each group. Then the proper length of the catheter, rat body weight, and the agent dosage were preliminarily evaluated for intrathecal administration. PSD-95siRNA(2μg/d X4d), saline, i-FectTM or control siRNA was given intrathecally(i.t). Mechanical allodynia and thermal hyperalgesia were measured to evaluate the analgesic effect of PSD-95siRNA. On the1st day and5th day after the last administration, rats were sacrificed and lumbar spinal cords were sampled for further real-time PCR analysis.
Results:
Chronic constriction injury of rat sciatic nerve produced a clear-cut mechanical allodynia and thermal hyepralgesia in rats submitted to the surgery compared to the sham operated and naive ones. Intrathecal PSD-95siRNA (2μg/d X3d, i.t.) could significantly reduce the level of PSD-95mRNA in the spinal cord, and intrathecal PSD-95siRNA (2μg/dX4d, i.t.) could elevate the mechanical withdrawal threshold and paw withdrawal thermal latency of CCI rats without affecting the baseline antinociception.
Conclusion:
The PSD-95mRNA level exhibited no chage in the superficial dorsal horn after chronic constriction injury of rat sciatic nerve. In vivo delivery of PSD-95siRNA using i-FectTM could significantly silent the target gene, as relieved neuropathic pain in CCI model rats.
已有实验证明PSD-95与神经病理性疼痛密切相关,而RNA干扰(RNA interference, RNAi)技术是近年研究比较热门的治疗方向。本研究旨在利用RNAi技术沉默大鼠脊髓PSD-95基因,并观察此方法治疗神经病理性疼痛的效果。
方法：
将30只雄性SD大鼠随机分成6组(n=5),分别为空白对照,假手术组(3天和7天),以及CCI模型(3天、7天、14天)组,通过测量机械性痛阈和热痛阈来判断CCI模型是否成功。术后第3天、第7天、第14天分别处死大鼠,留取脊髓标本,进行real-time PCR分析PSD-95mRNA表达水平的变化。取不同重量大鼠建立鞘内置管给药模型,置管次日鞘内注射2%利多卡因,判断鞘内置管是否成功,并评价不同重量大鼠置管深度与效果的关系。选取合适重量大鼠,分组后(n=6)进行鞘内置管,鞘内给予PSD-95小干扰RNA(small interfering RNA, siRNA),最后一次给药后1天、3天、5天分别测量痛行为变化,并于1天和5天处死动物,留取脊髓标本,进行real-time PCR分析PSD-95siRNA表达的变化。选取合适重量大鼠,分组(n=5)后进行鞘内置管,置管后3-4天建立坐左侧骨神经CCI(chronic constriction injury,'慢性压迫性损伤)模型,并鞘内分别给予PSD-95siRNA、生理盐水、转染试剂(i-FectTM)、阴性对照siRNA,在给药后1天和5天分别测量痛阈,并处死动物,留取脊髓标本,进行real-time PCR分析PSD-95mRNA表达水平的变化。
结果：
大鼠CCI模型手术侧后足机械性痛阈和热痛敏阈值明显下降(P<0.05),但脊髓背角PSD-95mRNA表达无明显变化。正常大鼠中,鞘内注射PSD-95siRNA可降低大鼠脊髓背角PSD-95mRNA表达水平(P<0.05),但对其痛阈无显著影响。鞘内注射PSD-95siRNA可明显缓解CCI模型大鼠的神经病理性疼痛(P<0.05)。
结论：
CCI模型大鼠其脊髓背角PSD-95mRNA表达水平无显著改变,鞘内注射PSD-95siRNA可以明显缓解CCI模型大鼠的热痛觉过敏和机械性痛觉异常。
Objective:
It is taught that PSD-95is involved in the generation and development of chronic neuropathic pain. RNAi (RNA interference) technique and small interfering RNA (siRNA) now offer a powerful and highly specific tool for therapeutic gene silencing. The aim of this study is to investigate the efficiency of PSD-95gene silencing by siRNA, together with its therapeutic effect on chronic constriction injury model rats.
Methods:
Ninety-six male SD rats, weighting200-250g were randomly divided into6groups (n=5for each group):Naive, Sham(sham3d and sham7d), CCI(CCI3d, CCI7d and CCI14d). Mechanical allodynia and thermal hyperalgesia were measured to evaluate the success of the model. The rats were executed on3rdd、7thd、14thd after the surgery, and the level of PSD-95mRNA was compared among each group. Then the proper length of the catheter, rat body weight, and the agent dosage were preliminarily evaluated for intrathecal administration. PSD-95siRNA(2μg/d X4d), saline, i-FectTM or control siRNA was given intrathecally(i.t). Mechanical allodynia and thermal hyperalgesia were measured to evaluate the analgesic effect of PSD-95siRNA. On the1st day and5th day after the last administration, rats were sacrificed and lumbar spinal cords were sampled for further real-time PCR analysis.
Results:
Chronic constriction injury of rat sciatic nerve produced a clear-cut mechanical allodynia and thermal hyepralgesia in rats submitted to the surgery compared to the sham operated and naive ones. Intrathecal PSD-95siRNA (2μg/d X3d, i.t.) could significantly reduce the level of PSD-95mRNA in the spinal cord, and intrathecal PSD-95siRNA (2μg/dX4d, i.t.) could elevate the mechanical withdrawal threshold and paw withdrawal thermal latency of CCI rats without affecting the baseline antinociception.
Conclusion:
The PSD-95mRNA level exhibited no chage in the superficial dorsal horn after chronic constriction injury of rat sciatic nerve. In vivo delivery of PSD-95siRNA using i-FectTM could significantly silent the target gene, as relieved neuropathic pain in CCI model rats.
引文
1 Hiroshi Ueda, et al. Molecular Mechanisms of Neuropathic Pain.Drug News Perspect 16(9), November 2003:605-611
2 Campbell, J.N. & Meyer, R.A. Mechanisms of neuropathic pain. Neuron 52,77-92 (2006).
3 Feng Tao,Yuan-xiang Tao et al. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. Neuroreport 2001;12:3251-3255.
4 Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110,563-574 (2002).
5 Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,391,806-811.
6 Charles X. Li,Amy Parker,Ellen Menocal,Shuanglin Xiang,Laura Borodyansky, Johannes H. Fruehauf Delivery of RNA Interference. Cell Cycle 5:18,2103-2109
7 Nakagawa, T., et al. Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions. Neuron 44,453-467 (2004).
8 Bennett, G. J., & Xie, Y. K. (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33(1),87-107
9 Seltzer, Z., Dubner, R., & Shir, Y. (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43(2),205-218.
10 Kim, S. H., Chung, J. M. (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50(3),355-363.
11 Decosterd, I. and Woolf, C.J. Spared nerve injury:An animal model of persistent peripheral neuropathic pain. Pain 2000,87:149-58.
12 Yaksh TL, Rudy TA(1976) Analgesia mediated by a direct spinal action of narcotics. Science192:1357-1358
13 Van den Hoogen RH, Colpaert FC. Long term catheterization of the lumbar epidural space in rats. Pharmacol Biochem Behav.1981 Sep;15(3):515-6.
14 Wang BC, Hillman DE, Li D, Turndorf H.Lumbar subarachnoid catheterization in rats. Pharmacol Biochem Behav.1991 Mar;38(3):685-8.
15 Lumbar catheterization of the spinal subarachnoid space in the rat. Storkson RV, Kjorsvik A, Tj(?)lsen A, Hole K. Neurosci Methods.1996 Apr;65(2):167-72.
16 Milligan ED, Hinde JL, Mehmert KK, Maier SF, Watkins LR. A method for increasing the viability of the external portion of lumbar catheters placed in the spinal subarachnoid space of rats. J Neurosci Methods.1999 Aug 1;90(1):81-6.
17 Pogatzki EM, Zahn PK, Brennan TJ. Lumbar catheterization of the subarachnoid space with a 32-gauge polyurethane catheter in the rat. Eur J Pain.2000;4(1):111-3
18 Palay, S.L. Synapses in the central nervous system. The Journal of biophysical and biochemical cytology 2,193-202 (1956).
19 Jordan, B.A., et al. Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics 3,857-871 (2004).
20 Ziff, E.B. Enlightening the postsynaptic density. Neuron 19,1163-1174 (1997).
21 Kim, E. & Sheng, M. PDZ domain proteins of synapses. Nature reviews 5,771-781 (2004).
22 Hung, A. Y. & Sheng, M. PDZ domains:structural modules for protein complex assembly. J Biol Chem 277,5699-5702 (2002).
23 Boyce, S., Wyatt, A., Webb, J.K., O'Donnell, R., Mason, G,21.Rigby, M., Sirinathsinghji, D., Hill, R.G, and Rupniak, N.M.J. Selective NMDANR2B antagonists induce antinociception without motor dysfunction:correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38:611-623
24 Andrei B. Petrenko, MD, Tomohiro Yamakura, MD, PhD, Hiroshi Baba, MD, PhD, and Koki Shimoji. The Role of N-Methyl-D-Aspartate (NMDA) Receptors in Pain:A Review. Anesth Analg 2003;97:1108-16
25 Emer M. Garry,1 Andrew Moss, et al。 Neuropathic Sensitization of Behavioral Reflexes and Spinal NMDA Receptor/CaM Kinase II Interactions Are Disrupted in PSD-95 Mutant Mice. Current Biology 2003;13:321-328.
26罗爱林金小高在SNI痛疼模型中脊髓背角转录PSD95与表达NMDA2B受体及nNOS的不一致性2005年中华医学会全国麻醉学术年会论文汇编
27 Peng HY, Chen GD, Tung KC, Lai CY, Hsien MC, Chiu CH, Lu HT, Liao JM, Lee SD, Lin TB. Colon mustard oil instillation induced cross-organ reflex sensitization on the pelvic-urethra reflex activity in rats. Pain.2009 Mar;142(1-2):75-88
28 Y.X. Tao. Expression of.PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor mediated thermal hyperalgesia in the spinal cord. Neuroscience.2000,98(2):201-206
29 Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
30 Elbashir, S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411,494-498 (2001).
31 Harborth, J., Elbashir, S.M., Bechert, K., Tuschl, T. & Weber, K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114,4557-4565(2001)
32 Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574 (2002)
33 Landen, C. N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., Sood, A. K. (2005). Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Res.65: 6910-6918.
34 Diaz-Hernandez, M., Torres-Peraza, J., Salvatori-Abarca, A., Moran, M. A., Gomez-Ramos, P., Alberch, J., Lucas, J. J. (2005). Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease. J. Neurosci.25:9773-9781.
35 Giladi,H., Ketzinel-Gilad,M., Rivkin,L., Felig,Y., Nussbaum,O. and Galun,E. (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther.,8, 769776.
36 Miaw-Chyi Luol, Dong-Qin Zhangl, Shou-Wu Ma, Yuan-Yuan Huangl,Sam J Shuster, Frank Porrecal and Josephine Lai. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Molecular Pain 2005, 1:29.
37 Bichoy H. Gabra, Fay K. Kessler, Joseph K. Ritter, William L. Dewey, and Forrest L. Smith. Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Levels by Intrathecal Short-Hairpin RNA Blocks Group I Metabotropic Glutamate Receptor-Mediated Hyperalgesia. JPET 322:186-194,2007.
38 X.-W. Dong, S.Goregoaker, H.Engler,X. Zhou.Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 146 (2007) 812-821
39 Tumati, S., et al., Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia, Eur. J. Pharmacol. (2008), doi:10.1016/j.ejphar.2008.10.033
40 Stathakis, D.G., et al. Genomic organization of human DLG4, the gene encoding postsynaptic density 95. J Neurochem 73,2250-2265 (1999).
41 C. Altier, C. S. Dale, A. E. Kisilevsky, K. Chapman, A. J. Castiglioni, E. A. Matthews, R. M. Evans, A. H. Dickenson, D. Lipscombe, N. Vergnolle, et al.Differential Role of N-Type Calcium Channel Splice Isoforms in Pain J. Neurosci., June 13,2007; 27(24): 6363-6373
42 Louis Dore-Savard, Genevieve Roussy1 Marc-Andre Dansereau, Michael A Collingwood, Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA:A Direct Application for Pain Research. Molecular Therapy vol.16 no.7,1331-1339 july 2008.
43 Tao F., Tao Y.-x., Mao P., Johns R. A. Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience 117(2003) 731-739
1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,391,806-811.
2. Landen, C. N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G, Sood, A. K. (2005). Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Res.65: 6910-6918.
3. Diaz-Hernandez, M, Torres-Peraza, J., Salvatori-Abarca, A., Moran, M. A., Gomez-Ramos, P., Alberch, J., Lucas, J. J. (2005). Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease.J.Neurosci.25:9773-9781.
4. Giladi,H., Ketzinel-Gilad,M., Rivkin,L., Felig,Y., Nussbaum,O. and Galun,E. (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther.,8, 769776.
5. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C,Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005; 54:1298-308.
6. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72.
7. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-66
8. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11:675-82.
9. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005; 33:439-47.
10. Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene 2000; 19:6651-9.
11. Chiu YL, Rana TM. siRNA function in RNAi:A chemical modification analysis. Rna 2003; 9:1034-48.
12. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005;41:1349-56.
13. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005; 48:4247-53.
14. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004). Nature 432,173-178
15. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna 2004; 10:766-71.
16. Flynn MA, Casey DG, Todryk SM, Mahon BP. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) 2004; 1:4.
17. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327:761-6.
18. Landen Jr CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65:6910-8.
19. G.P. Tang, J.M. Zeng, S.J. Gao, Y.X. Ma, L. Shi, Y. Li, H.-P. Toob, S. Wang Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 24 (2003) 2351-2362
20. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676-81.
21. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12:461-6.
22. Xu Wang, Chaoyang Wang, Jieming Zeng, Xiaoyun Xu, Peter Y.K. Hwang, Woon-Chee Yee, Yee-Kong Ng, and Shu Wang. Gene Transfer to Dorsal Root Ganglia by Intrathecal Injection:Effects on Regeneration of Peripheral Nerves. MOLECULAR THERAPY Vol.12, No.2, August 2005
23. P-H Tan, L-C Yang, H-C Shih, K-C Lan and J-T Cheng. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-inducednociception in the rat. Gene Therapy (2005) 12,59-66
24. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23:1002-7.
25. Derek M. Dykxhoorn and Judy Lieberman. Knocking down Disease with siRNAs. DOI 10.1016/j.cell.2006.07.007
26. Morrissey, D.V., Lockridge, J.A., Shaw, L.,Blanchard, K., Jensen, K., Breen, W., Hartsough,K., Machemer, L., Radka, S., Jadhav, V.,et al. (2005). Nat. Biotechnol.23, 1002-1007.
27. Zimmermann, T.S., Lee, A.C., Akinc, A.,Bramlage, B., Bumcrot, D., Fedoruk, M.N.,Harborth, J., Heyes, J.A., Jeffs, L.B., John,M., et al. (2006). Nature 441, 111-114.
28. Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003; 5:1039-45.
29. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32:e149.
30. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002; 62:5139-43.
31. Theng Ong S, Li F, Du J, Tan YW, Wang S. Hybrid cytomegalovirus Enhancer-H1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference. Hum Gene Ther 2005.
32. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243-247.
33. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE. American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy 2003;8:180-7.
34. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6.
35. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2004; 2:9.
36. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.2005; 8:1343-9.
37. Federica Locatelli, MD,1,2 Stefania Corti, MD,1,3 Dimitra Papadimitriou, MD et al. Fas Small Interfering RNA Reduces Motoneuron Death in Amyotrophic Lateral Sclerosis Mice. Ann Neurol 2007;62:81-92
38. Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer.Semin Oncol 2005; 32:573-82.
39. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20:1006-10.
40. Chen Y, Chen H, Hoffmann A, Cool DR, Diz DI, Chappell MC, Chen A, Morris M. Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension 2005, (01.HYP.0000200259.0000201947.bb).
41. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128:2029-41.
42. Gurzov EN, Izquierdo M. RNA interference against Heel inhibits tumor growth in vivo.2005; 13:1-7.
43. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005; 65:10680-5.
44. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellularcarcinoma growth in vitro and in vivo. Mol Cancer Ther 2005; 4:1577-84.
45. Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucl Acids Res 2004;32:e134.
46. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-[alpha]-dependent induction of TRB-3.2004; 10:530-4.
47. Charles X. Li,Amy Parker,Ellen Menocal,Shuanglin Xiang,Laura Borodyansky,Johannes H. Fruehauf Delivery of RNA Interference. Cell Cycle 5:18, 2103-2109.
48. Feng Tao, Yuan-Xiang Tao, Julio A. Gonzalez, Ming Fang, Peizhong Mao and Roger A. Johns. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. NEUROREPORT Vol 12 No 15 29 October 2001
49. C. Altier, C. S. Dale, A. E. Kisilevsky, K. Chapman, A. J. Castiglioni, E. A. Matthews, R. M. Evans, A. H. Dickenson, D. Lipscombe, N. Vergnolle, et al.Differential Role of N-Type Calcium Channel Splice Isoforms in Pain J. Neurosci., June 13,2007; 27(24):6363-6373
50. Guo W., Robbins M. T., Wei F., Zou S., Dubner R. and Ren K. (2006) Supraspinal brain-derived neurotrophic factor signaling:a novel mechanism for descending pain facilitation. J. Neurosci.26,126- 137.
51. Thomas Christoph, Arnold Gru"nweller, Joanna Mika, Martin K.-H. Scha"fer. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochemical and Biophysical Research Communications 350 (2006) 238-243
52. Susumu Kasama, Masatomo Kawakubo, Takefumi Suzuki, Tomoko Nishizawa, Akiko Ishida and Jun Nakayama. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepawinflammatory hyperalgesia in rat。 European Journal ofNeuroscience, Vol.25, pp.2956-2963,2007
53. Bichoy H. Gabra, Fay K. Kessler, Joseph K. Ritter, William L. Dewey, and Forrest L. Smith. Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Levels by Intrathecal Short-Hairpin RNA Blocks Group I Metabotropic Glutamate Receptor-Mediated Hyperalgesia. JPET 322:186-194,2007
54. Louis Dore-Savard, Genevieve Roussy, Marc-Andre Dansereau, Michael A Collingwood,Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA:A Direct Application for Pain Research. Molecular Therapy vol.16 no.7,1331-1339 July 2008
55. Miaw-Chyi Luo, Dong-Qin Zhang, Shou-Wu Ma, Yuan-Yuan Huang,Sam J Shuster, Frank Porreca and Josephine Lai. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Molecular Pain 2005, 1:29 doi:10.1186/1744-8069-1-29
56. Tumati, S., et al., Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia, Eur. J. Pharmacol. (2008), doi:10.1016/j.ejphar.2008.10.033
57. X.-W. DONG S. GOREGOAKER H. ENGLER, X. ZHOU, L. MARK, J. CRONA, R. TERRY, J. HUNTER.SMALL INTERFERING RNA-MEDIATED SELECTIVE KNOCKDOWN OF NaV1.8 TETRODOTOXIN-RESISTANT SODIUM CHANNEL REVERSES MECHANICAL ALLODYNIA IN NEUROPATHIC RATS. Neuroscience 146 (2007) 812-821
58. P-H Tan, L-C Yang, H-C Shih, K-C Lan and J-T Cheng. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Therapy (2005) 12,59-66
2 Campbell, J.N. & Meyer, R.A. Mechanisms of neuropathic pain. Neuron 52,77-92 (2006).
3 Feng Tao,Yuan-xiang Tao et al. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. Neuroreport 2001;12:3251-3255.
4 Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110,563-574 (2002).
5 Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,391,806-811.
6 Charles X. Li,Amy Parker,Ellen Menocal,Shuanglin Xiang,Laura Borodyansky, Johannes H. Fruehauf Delivery of RNA Interference. Cell Cycle 5:18,2103-2109
7 Nakagawa, T., et al. Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions. Neuron 44,453-467 (2004).
8 Bennett, G. J., & Xie, Y. K. (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33(1),87-107
9 Seltzer, Z., Dubner, R., & Shir, Y. (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43(2),205-218.
10 Kim, S. H., Chung, J. M. (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50(3),355-363.
11 Decosterd, I. and Woolf, C.J. Spared nerve injury:An animal model of persistent peripheral neuropathic pain. Pain 2000,87:149-58.
12 Yaksh TL, Rudy TA(1976) Analgesia mediated by a direct spinal action of narcotics. Science192:1357-1358
13 Van den Hoogen RH, Colpaert FC. Long term catheterization of the lumbar epidural space in rats. Pharmacol Biochem Behav.1981 Sep;15(3):515-6.
14 Wang BC, Hillman DE, Li D, Turndorf H.Lumbar subarachnoid catheterization in rats. Pharmacol Biochem Behav.1991 Mar;38(3):685-8.
15 Lumbar catheterization of the spinal subarachnoid space in the rat. Storkson RV, Kjorsvik A, Tj(?)lsen A, Hole K. Neurosci Methods.1996 Apr;65(2):167-72.
16 Milligan ED, Hinde JL, Mehmert KK, Maier SF, Watkins LR. A method for increasing the viability of the external portion of lumbar catheters placed in the spinal subarachnoid space of rats. J Neurosci Methods.1999 Aug 1;90(1):81-6.
17 Pogatzki EM, Zahn PK, Brennan TJ. Lumbar catheterization of the subarachnoid space with a 32-gauge polyurethane catheter in the rat. Eur J Pain.2000;4(1):111-3
18 Palay, S.L. Synapses in the central nervous system. The Journal of biophysical and biochemical cytology 2,193-202 (1956).
19 Jordan, B.A., et al. Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics 3,857-871 (2004).
20 Ziff, E.B. Enlightening the postsynaptic density. Neuron 19,1163-1174 (1997).
21 Kim, E. & Sheng, M. PDZ domain proteins of synapses. Nature reviews 5,771-781 (2004).
22 Hung, A. Y. & Sheng, M. PDZ domains:structural modules for protein complex assembly. J Biol Chem 277,5699-5702 (2002).
23 Boyce, S., Wyatt, A., Webb, J.K., O'Donnell, R., Mason, G,21.Rigby, M., Sirinathsinghji, D., Hill, R.G, and Rupniak, N.M.J. Selective NMDANR2B antagonists induce antinociception without motor dysfunction:correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38:611-623
24 Andrei B. Petrenko, MD, Tomohiro Yamakura, MD, PhD, Hiroshi Baba, MD, PhD, and Koki Shimoji. The Role of N-Methyl-D-Aspartate (NMDA) Receptors in Pain:A Review. Anesth Analg 2003;97:1108-16
25 Emer M. Garry,1 Andrew Moss, et al。 Neuropathic Sensitization of Behavioral Reflexes and Spinal NMDA Receptor/CaM Kinase II Interactions Are Disrupted in PSD-95 Mutant Mice. Current Biology 2003;13:321-328.
26罗爱林金小高在SNI痛疼模型中脊髓背角转录PSD95与表达NMDA2B受体及nNOS的不一致性2005年中华医学会全国麻醉学术年会论文汇编
27 Peng HY, Chen GD, Tung KC, Lai CY, Hsien MC, Chiu CH, Lu HT, Liao JM, Lee SD, Lin TB. Colon mustard oil instillation induced cross-organ reflex sensitization on the pelvic-urethra reflex activity in rats. Pain.2009 Mar;142(1-2):75-88
28 Y.X. Tao. Expression of.PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor mediated thermal hyperalgesia in the spinal cord. Neuroscience.2000,98(2):201-206
29 Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
30 Elbashir, S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411,494-498 (2001).
31 Harborth, J., Elbashir, S.M., Bechert, K., Tuschl, T. & Weber, K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114,4557-4565(2001)
32 Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574 (2002)
33 Landen, C. N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., Sood, A. K. (2005). Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Res.65: 6910-6918.
34 Diaz-Hernandez, M., Torres-Peraza, J., Salvatori-Abarca, A., Moran, M. A., Gomez-Ramos, P., Alberch, J., Lucas, J. J. (2005). Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease. J. Neurosci.25:9773-9781.
35 Giladi,H., Ketzinel-Gilad,M., Rivkin,L., Felig,Y., Nussbaum,O. and Galun,E. (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther.,8, 769776.
36 Miaw-Chyi Luol, Dong-Qin Zhangl, Shou-Wu Ma, Yuan-Yuan Huangl,Sam J Shuster, Frank Porrecal and Josephine Lai. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Molecular Pain 2005, 1:29.
37 Bichoy H. Gabra, Fay K. Kessler, Joseph K. Ritter, William L. Dewey, and Forrest L. Smith. Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Levels by Intrathecal Short-Hairpin RNA Blocks Group I Metabotropic Glutamate Receptor-Mediated Hyperalgesia. JPET 322:186-194,2007.
38 X.-W. Dong, S.Goregoaker, H.Engler,X. Zhou.Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 146 (2007) 812-821
39 Tumati, S., et al., Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia, Eur. J. Pharmacol. (2008), doi:10.1016/j.ejphar.2008.10.033
40 Stathakis, D.G., et al. Genomic organization of human DLG4, the gene encoding postsynaptic density 95. J Neurochem 73,2250-2265 (1999).
41 C. Altier, C. S. Dale, A. E. Kisilevsky, K. Chapman, A. J. Castiglioni, E. A. Matthews, R. M. Evans, A. H. Dickenson, D. Lipscombe, N. Vergnolle, et al.Differential Role of N-Type Calcium Channel Splice Isoforms in Pain J. Neurosci., June 13,2007; 27(24): 6363-6373
42 Louis Dore-Savard, Genevieve Roussy1 Marc-Andre Dansereau, Michael A Collingwood, Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA:A Direct Application for Pain Research. Molecular Therapy vol.16 no.7,1331-1339 july 2008.
43 Tao F., Tao Y.-x., Mao P., Johns R. A. Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience 117(2003) 731-739
1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,391,806-811.
2. Landen, C. N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G, Sood, A. K. (2005). Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Res.65: 6910-6918.
3. Diaz-Hernandez, M, Torres-Peraza, J., Salvatori-Abarca, A., Moran, M. A., Gomez-Ramos, P., Alberch, J., Lucas, J. J. (2005). Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease.J.Neurosci.25:9773-9781.
4. Giladi,H., Ketzinel-Gilad,M., Rivkin,L., Felig,Y., Nussbaum,O. and Galun,E. (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther.,8, 769776.
5. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C,Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005; 54:1298-308.
6. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72.
7. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-66
8. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11:675-82.
9. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005; 33:439-47.
10. Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene 2000; 19:6651-9.
11. Chiu YL, Rana TM. siRNA function in RNAi:A chemical modification analysis. Rna 2003; 9:1034-48.
12. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005;41:1349-56.
13. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005; 48:4247-53.
14. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004). Nature 432,173-178
15. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna 2004; 10:766-71.
16. Flynn MA, Casey DG, Todryk SM, Mahon BP. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) 2004; 1:4.
17. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327:761-6.
18. Landen Jr CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65:6910-8.
19. G.P. Tang, J.M. Zeng, S.J. Gao, Y.X. Ma, L. Shi, Y. Li, H.-P. Toob, S. Wang Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 24 (2003) 2351-2362
20. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676-81.
21. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12:461-6.
22. Xu Wang, Chaoyang Wang, Jieming Zeng, Xiaoyun Xu, Peter Y.K. Hwang, Woon-Chee Yee, Yee-Kong Ng, and Shu Wang. Gene Transfer to Dorsal Root Ganglia by Intrathecal Injection:Effects on Regeneration of Peripheral Nerves. MOLECULAR THERAPY Vol.12, No.2, August 2005
23. P-H Tan, L-C Yang, H-C Shih, K-C Lan and J-T Cheng. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-inducednociception in the rat. Gene Therapy (2005) 12,59-66
24. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23:1002-7.
25. Derek M. Dykxhoorn and Judy Lieberman. Knocking down Disease with siRNAs. DOI 10.1016/j.cell.2006.07.007
26. Morrissey, D.V., Lockridge, J.A., Shaw, L.,Blanchard, K., Jensen, K., Breen, W., Hartsough,K., Machemer, L., Radka, S., Jadhav, V.,et al. (2005). Nat. Biotechnol.23, 1002-1007.
27. Zimmermann, T.S., Lee, A.C., Akinc, A.,Bramlage, B., Bumcrot, D., Fedoruk, M.N.,Harborth, J., Heyes, J.A., Jeffs, L.B., John,M., et al. (2006). Nature 441, 111-114.
28. Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003; 5:1039-45.
29. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32:e149.
30. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002; 62:5139-43.
31. Theng Ong S, Li F, Du J, Tan YW, Wang S. Hybrid cytomegalovirus Enhancer-H1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference. Hum Gene Ther 2005.
32. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243-247.
33. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE. American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy 2003;8:180-7.
34. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6.
35. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2004; 2:9.
36. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.2005; 8:1343-9.
37. Federica Locatelli, MD,1,2 Stefania Corti, MD,1,3 Dimitra Papadimitriou, MD et al. Fas Small Interfering RNA Reduces Motoneuron Death in Amyotrophic Lateral Sclerosis Mice. Ann Neurol 2007;62:81-92
38. Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer.Semin Oncol 2005; 32:573-82.
39. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20:1006-10.
40. Chen Y, Chen H, Hoffmann A, Cool DR, Diz DI, Chappell MC, Chen A, Morris M. Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension 2005, (01.HYP.0000200259.0000201947.bb).
41. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128:2029-41.
42. Gurzov EN, Izquierdo M. RNA interference against Heel inhibits tumor growth in vivo.2005; 13:1-7.
43. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005; 65:10680-5.
44. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellularcarcinoma growth in vitro and in vivo. Mol Cancer Ther 2005; 4:1577-84.
45. Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucl Acids Res 2004;32:e134.
46. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-[alpha]-dependent induction of TRB-3.2004; 10:530-4.
47. Charles X. Li,Amy Parker,Ellen Menocal,Shuanglin Xiang,Laura Borodyansky,Johannes H. Fruehauf Delivery of RNA Interference. Cell Cycle 5:18, 2103-2109.
48. Feng Tao, Yuan-Xiang Tao, Julio A. Gonzalez, Ming Fang, Peizhong Mao and Roger A. Johns. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. NEUROREPORT Vol 12 No 15 29 October 2001
49. C. Altier, C. S. Dale, A. E. Kisilevsky, K. Chapman, A. J. Castiglioni, E. A. Matthews, R. M. Evans, A. H. Dickenson, D. Lipscombe, N. Vergnolle, et al.Differential Role of N-Type Calcium Channel Splice Isoforms in Pain J. Neurosci., June 13,2007; 27(24):6363-6373
50. Guo W., Robbins M. T., Wei F., Zou S., Dubner R. and Ren K. (2006) Supraspinal brain-derived neurotrophic factor signaling:a novel mechanism for descending pain facilitation. J. Neurosci.26,126- 137.
51. Thomas Christoph, Arnold Gru"nweller, Joanna Mika, Martin K.-H. Scha"fer. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochemical and Biophysical Research Communications 350 (2006) 238-243
52. Susumu Kasama, Masatomo Kawakubo, Takefumi Suzuki, Tomoko Nishizawa, Akiko Ishida and Jun Nakayama. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepawinflammatory hyperalgesia in rat。 European Journal ofNeuroscience, Vol.25, pp.2956-2963,2007
53. Bichoy H. Gabra, Fay K. Kessler, Joseph K. Ritter, William L. Dewey, and Forrest L. Smith. Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Levels by Intrathecal Short-Hairpin RNA Blocks Group I Metabotropic Glutamate Receptor-Mediated Hyperalgesia. JPET 322:186-194,2007
54. Louis Dore-Savard, Genevieve Roussy, Marc-Andre Dansereau, Michael A Collingwood,Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA:A Direct Application for Pain Research. Molecular Therapy vol.16 no.7,1331-1339 July 2008
55. Miaw-Chyi Luo, Dong-Qin Zhang, Shou-Wu Ma, Yuan-Yuan Huang,Sam J Shuster, Frank Porreca and Josephine Lai. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Molecular Pain 2005, 1:29 doi:10.1186/1744-8069-1-29
56. Tumati, S., et al., Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia, Eur. J. Pharmacol. (2008), doi:10.1016/j.ejphar.2008.10.033
57. X.-W. DONG S. GOREGOAKER H. ENGLER, X. ZHOU, L. MARK, J. CRONA, R. TERRY, J. HUNTER.SMALL INTERFERING RNA-MEDIATED SELECTIVE KNOCKDOWN OF NaV1.8 TETRODOTOXIN-RESISTANT SODIUM CHANNEL REVERSES MECHANICAL ALLODYNIA IN NEUROPATHIC RATS. Neuroscience 146 (2007) 812-821
58. P-H Tan, L-C Yang, H-C Shih, K-C Lan and J-T Cheng. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Therapy (2005) 12,59-66